HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Abstract
Rituximab induces B-cell depletion; therefore, it has been used in the treatment of immune thrombocytopenic purpura (ITP). The aim of this retrospective study was to evaluate the effectiveness of rituximab in the treatment of 89 patients with chronic ITP refractory to several treatments. All the patients had platelet counts <30 x 10(9)/l. They had received a median of five (2-13) previous treatments, and 47 had undergone splenectomy. Rituximab was administered i.v. at 375 mg/m(2) in four weekly doses in 77 patients, and 12 patients received 1-6 doses. Forty-nine patients (55.1%) reached platelet counts >50 x 10(9)/l; 41 (46%) achieved a complete response (CR; platelets >100 x 10(9)/l), and eight (9%) obtained a partial response (platelets 50-100 x 10(9)/l). Overall, 31 patients (35%) maintained response, including 15 patients in whom splenectomy failed, with a median follow-up of 9 months (2-42), 12 for more than 1 year. The unique predictor of a maintained response was to reach a CR. Heavily treated patients (more than three different previous treatments, including any corticosteroids) and those with longer ITP duration (>10 years from diagnosis) had a worse response. Non-splenectomized patients had a better early response rate than those splenectomized. Rituximab was well tolerated, with two fever episodes following infusion and two reports of skin rash. Rituximab induced clinical responses in multi-treated refractory ITP patients with little toxicity and should be considered as an early therapeutic option in this setting, even as an alternative to splenectomy in selected patients.
AuthorsFrancisco Javier Peñalver, Victor Jiménez-Yuste, Manuel Almagro, Alberto Alvarez-Larrán, Lluis Rodríguez, Marisol Casado, Laura Gallur, Pilar Giraldo, Roberto Hernández, Dolores Menor, Maria José Rodríguez, Dolores Caballero, Raúl González, José Mayans, Isabel Millán, José Rafael Cabrera,
JournalAnnals of hematology (Ann Hematol) Vol. 85 Issue 6 Pg. 400-6 (Jun 2006) ISSN: 0939-5555 [Print] Germany
PMID16550390 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Child
  • Child, Preschool
  • Exanthema (chemically induced)
  • Female
  • Fever (chemically induced)
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Platelet Count (methods)
  • Purpura, Thrombocytopenic, Idiopathic
  • Retrospective Studies
  • Rituximab
  • Spain
  • Splenectomy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: